Source: Annual Congress 2002 - Prevalence and costs of COPD
Disease area: Airway diseases

Abstract

INTRODUCTION The recent NHLBI/WHO Global Initiative for COPD workshop report states that little economic information concerning COPD is available. This research contributes to the economic information on COPD for the Netherlands.
OBJECTIVE Existing studies present the costs per year per patient and total costs for the Netherlands (Rutten-van Molken, M.P.M.H. et al. Resp Med 1999;93:779-87, Feenstra, T.L. et al. AJRCCM 2001;164:590-6). The purpose of the current research is to update these studies and additionally to compute the lifelong use of care by COPD patients and the related lifetime costs of illness.
METHODS The average life expectancy of a new COPD patient was computed with a dynamic lifetable model. Data on resource use and costs for three age groups and nine types of care were taken from large representative registrations. Sensitivity analyses were performed for instance for the costs of a day in hospital and medication costs.
RESULTS The model calculates a remaining life expectancy for new COPD patients that varies from 26 years for women diagnosed at age 45 to 2 years for men diagnosed at age 87. On average it is 4 years less than the life expectancy for the general population. A baseline estimates of expected lifetime costs at incidence is EURO 8.1 thousand for new COPD patients of 45 years and older. Hospital and medication are the most important types of care in terms of costs. Together, they contribute between 60% and 80% of expected lifetime costs.
CONCLUSION The number of COPD patients is known to grow in the nearby future. The above results could help to understand the increasing healthcare needs of these patients. They reflect the importance of hospital care and medication for the (total costs of) care of COPD.

Rating:

Share or cite this content

Citations should be made in the following way:
T. L. Feenstra, M. P. M. H. Rutten-van Molken, M. M. L. van Genugten (Bilthoven, Rotterdam, The Netherlands). Lifetime costs of COPD in the Netherlands. Eur Respir J 2002; 20: Suppl. 38, 829

Member's Comments

No comment yet.

Related content which might interest you: Projections of future costs of asthma and COPD in the Netherlands Source: Eur Respir J 2005; 26: Suppl. 49, 383s Year: 2005 Health care utilization and costs of asthma and COPD in the Netherlands Source: Eur Respir J 2005; 26: Suppl. 49, 383s Year: 2005 Costs of COPD and asthma in Sweden Source: Eur Respir J 2004; 24: Suppl. 48, 701s Year: 2004 Societal costs of severe asthma in Sweden Source: International Congress 2018 – Epidemiology of asthma and allergy: prevalence, incidence and risk factors Year: 2018 The costs of adult asthma in Denmark Source: Annual Congress 2011 - Comorbidities and impact on society of asthma and COPD Year: 2011 Epidemiology and costs of COPD Source: Eur Respir J 2006; 28: 1290 Year: 2006 Costs of asthma care in Belgium Source: Eur Respir J 2001; 18: Suppl. 33, 441s Year: 2001 The drug costs associated with COPD prescription medicine in Denmark Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Asthma: prevalence and cost of illness Source: Eur Respir J 2005; 25: 47-53 Year: 2005 Alcohol consumption and hospitalisations due to COPD Source: Eur Respir J 2001; 18: Suppl. 33, 274s Year: 2001 Trends in COPD-related hospitalisations in Sweden Source: Eur Respir J 2003; 22: Suppl. 45, 217s Year: 2003 Risk factors for self-reported hospitalizations among stable outpatients with COPD Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Predictive value of annual costs on 3-year mortality in COPD Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes Year: 2015 Prescription rates for various classes of COPD & asthma medication in Turkey Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001 Active tobacco smoking and costs of COPD exacerbations in secondary medical care in Poland Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Severity distribution of physician-diagnosed COPD in the Netherlands Source: Eur Respir J 2003; 22: Suppl. 45, 67s Year: 2003 Social distancing and admissions for severe exacerbations of COPD – a nationwide study Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Trends in the lifetime risk of COPD exacerbation requiring hospitalisation Source: Eur Respir J 2013; 42: 964-971 Year: 2013 Corerelation of COPD exacerbation with comorbidities, Lung function and mortality within a single-practice primary-care cohort in the UK Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019